Oncopeptides AB (ONPPF)
0.265
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
Oncopeptides Total Liabilities (Quarterly): 14.80M for Sept. 30, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 14.80M |
| June 30, 2023 | 16.47M |
| March 31, 2023 | 8.544M |
| December 31, 2022 | 8.734M |
| September 30, 2022 | 8.596M |
| June 30, 2022 | 8.886M |
| March 31, 2022 | 15.37M |
| December 31, 2021 | 25.26M |
| September 30, 2021 | 24.49M |
| June 30, 2021 | 30.96M |
| March 31, 2021 | 40.68M |
| December 31, 2020 | 45.17M |
| September 30, 2020 | 27.91M |
| June 30, 2020 | 29.19M |
| Date | Value |
|---|---|
| March 31, 2020 | 15.98M |
| December 31, 2019 | 21.03M |
| September 30, 2019 | 15.41M |
| June 30, 2019 | 23.33M |
| March 31, 2019 | 13.61M |
| December 31, 2018 | 14.33M |
| September 30, 2018 | 14.85M |
| June 30, 2018 | 14.64M |
| March 31, 2018 | 10.43M |
| December 31, 2017 | 7.559M |
| September 30, 2017 | 6.235M |
| June 30, 2017 | 7.399M |
| December 31, 2016 | 3.231M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
8.544M
Minimum
Mar 2023
45.17M
Maximum
Dec 2020
21.16M
Average
18.75M
Median
Total Liabilities (Quarterly) Benchmarks
| Abliva AB | 1.667M |
| Karolinska Development AB | 1.233M |
| Calliditas Therapeutics AB | 151.43M |
| Olink Holding AB | 81.33M |
| BioInvent International AB | 9.011M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 27.02M |
| Shareholders Equity (Quarterly) | 12.22M |
| Debt to Equity Ratio | 0.8095 |
| Current Ratio | 6.678 |
| Net Debt Paydown Yield | -2.57% |